Test Code DHTS Dihydrotestosterone, Serum
Reporting Name
Dihydrotestosterone, SUseful For
Monitoring patients receiving 5-alpha reductase inhibitor therapy or chemotherapy
Evaluating patients with possible 5-alpha reductase deficiency
Testing Algorithm
For more information see Steroid Pathways.
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
SerumSpecimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
0.6 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 90 days | ||
Ambient | 28 days |
Special Instructions
Reference Values
Males
Cord blood: ≤100 pg/mL
≤6 months: ≤1,200 pg/mL
Tanner Stages
Mean |
Age |
Reference range (pg/mL) |
Stage I (>6 months and prepubertal) |
7.1 years |
≤50 |
Stage II |
12.1 years |
≤200 |
Stage III |
13.6 years |
80-330 |
Stage IV |
15.1 years |
220-520 |
Stage V |
18 years |
240-650 |
>19 years: 112-955 pg/mL
Females
Cord blood: ≤50 pg/mL
≤6 months: ≤1,200 pg/mL
Tanner Stages
Mean |
Age |
Reference range (pg/mL) |
Stage I (>6 months and prepubertal) |
7.1 years |
≤50 |
Stage II |
10.5 years |
≤300 |
Stage III |
11.6 years |
≤300 |
Stage IV |
12.3 years |
≤300 |
Stage V |
14.5 years |
≤300 |
20-55 years: ≤300 pg/mL
>55 years: ≤128 pg/mL
1. Pang S, Levine LS, Chow D, Sagiani F, Saenger P, New MI. Dihydrotestosterone and its relationship to testosterone in infancy and childhood. J Clin Endocrinol Metab. 1979;48(5):821-826
2. Stanczyk FZ. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract Res Clin Endocrinol Metab. 2006;20(2):177-191
Day(s) Performed
Monday, Wednesday, Friday
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82642
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
DHTS | Dihydrotestosterone, S | 1848-1 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
81479 | Dihydrotestosterone, S | 1848-1 |
Interpretation
Patients taking 5-alpha reductase inhibitor have decreased dihydrotestosterone (DHT) serum levels.
Patients with genetic 5-alpha reductase deficiency (a rare disease) also have reduced DHT serum levels.
DHT should serve as the primary marker of peripheral androgen production. However, because it is metabolized rapidly and has a very high affinity for sex hormone-binding globulin, DHT does not reflect peripheral androgen action. Instead, its distal metabolite, 3-alpha, 17-beta-androstanediol glucuronide, serves as a better marker of peripheral androgen action.
For more information see Steroid Pathways.
Clinical Reference
1. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol. 2002;19(6):413-425
2. Trueb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37(8-9):981-990
3. Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem. 2000;7(2):211-247
4. Rhodes L, Harper J, Uno H, et al. The effects of finasteride (Proscar) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail macaques (Macaca arctoides). J Clin Endocrinol Metab. 1994;79(4):991-996
5. Gustafsson O, Norming U, Gustafsson S, Eneroth P, Astrom G, Nyman CR. Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population. Br J Urol. 1996;77(3):433-440
6. van der Veen A, van Faassen M, de Jong WHA, van Beek AP, Dijck-Brouwer DAJ, Kema IP. Development and validation of a LC-MS/MS method for the establishment of reference intervals and biological variation for five plasma steroid hormones. Clin Biochem. 2019;68:15-23. doi:10.1016/j.clinbiochem.2019.03.013
Report Available
2 to 8 daysMethod Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Portions of this test are covered by patents held by Quest Diagnostics